HIV researchers welcome TGA approval of Truvada for pre-exposure prophylaxis HIV prevention

The Kirby Institute at UNSW Australia welcomes the announcement that the Therapeutic Goods Administration (TGA) has approved the use of Truvada, an antiretroviral therapy currently used to treat HIV, to be prescribed in Australia as a pre-exposure prophylaxis (PrEP) for people who are HIV negative but at high-risk of contracting the virus.
This announcement comes as Australian leaders in HIV prevention, including researchers, health service providers, community organisations and state and territory health providers meet at the Kirby Institute to discuss the national implementation of PrEP as a strategy for the elimination of HIV transmission in Australia.
“There is an overwhelming body of evidence that supports the use of PrEP as an effective HIV prevention strategy,” said Professor Andrew Grulich, head of the HIV Epidemiology and Prevention program at the Kirby Institute. “Last year our PrELUDE study found that PrEP is feasible in real life situations.”
“Today we have key representatives from every state and territory in the country meeting at the Kirby Institute to discuss national guidelines and clinical practice for the use of PrEP,” said Professor Grulich. “For a fraction of the cost of treating someone for HIV, PrEP has the potential to prevent hundreds of new HIV infections in Australia. This is why PrEP is a game-changer in HIV prevention. TGA approval of Truvada for PrEP is a vital step in ensuring that people who want to use PrEP can access it.”

Director of the Kirby Institute, Professor David Cooper has been working in HIV prevention and treatment for more than 30 years. “For the first time since the beginning of the epidemic we are realistically talking about ending HIV transmission in Australia,” said Professor Cooper. “This is an exciting time for HIV prevention.”

“The next step is to ensure that the treatment is listed on the Pharmaceutical Benefits Scheme so that it is affordable and provides equitable access to those who need it,” said Professor Cooper.

The Pharmaceutical Benefits Advisory Committee is considering funding Truvada for PrEP at its July meeting.
Stakeholder quote:
"We have a national, bipartisan commitment to virtually eliminate HIV transmission in Australia by 2020.  That's only four years away, and although we have a long way to go, affordable, PBS-listed PrEP would make all the difference. Without PBS listing, this is a wasted tool. The Government must urgently fund PrEP in order to prevent many of the 1,100 HIV diagnoses that occur every year."
Darryl O'Donnell, Executive Director of Australian Federation of AIDS Organistions (AFAO) Click here to read AFAO's press release 


Media requests:
Lucienne Bamford
Communications Officer
The Kirby Institute, UNSW Australia
+61 (02) 9385 0550

About the Kirby Institute

The Kirby Institute at UNSW Australia is one of Australia’s premier infectious diseases research institutes. Based in Sydney, the Kirby Institute is funded by the Australian Government to conduct research into the HIV epidemic, viral hepatitis, blood-borne viruses, and sexually transmissible infections in Australia. The Kirby Institute is a centre of UNSW Medicine. 

Date published: 
Friday, 6 May 2016